Aclaris therapeutics posts quarterly loss per share $0.28

Aclaris therapeutics reports second quarter 2020 financial results and provides research and development and business highlights.aclaris therapeutics - qtrly loss per share $0.28.aclaris therapeutics - anticipates that cash, equivalents & marketable securities as of june 30 to be sufficient to fund operations through q1 2022.aclaris therapeutics - as of june 30, cash, equivalents & marketable securities of $68.1 million.aclaris therapeutics - expects to submit ind for ati-2138 in 2021.
ACRS Ratings Summary
ACRS Quant Ranking